[Therapy of Helicobacter infection].
Infection with Helicobacter pylori (H.p.) leads to mostly asymptomatic chronic gastritis. However, H.p. plays a role in peptic ulcer, giant fold gastritis (Menetrier's disease), and possibly in gastric carcinoma and low-grade MALT lymphoma. Whether functional dyspepsia also represents a Helicobacter-induced entity is questionable. H.p. should be eradicated in patients with peptic ulcer disease, Menetrier+s disease and - but in controlled studies only - in MALT lymphomas. Triple therapy with low-dose proton pump inhibitors and two antibiotics is the most favourable treatment compared to dual therapy with omeprazole and amoxicillin/clarithromycin despite the unresolved question of the development of drug resistance.
Koop
H
H
II. Innere Klinik-Gastroenterologie, Klinikum Buch, Berlin.
D000900:Anti-Bacterial Agents; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004415:Dyspepsia / Q000382:microbiology; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology; D010437:Peptic Ulcer / Q000382:microbiology; D013274:Stomach Neoplasms / Q000382:microbiology
D000900:Anti-Bacterial Agents; D005765:Gastrointestinal Agents
Therapie der Helicobacter-Infektion.